Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury

Gut

Volumn 41, Issue 4, 1997, Pages

  Maria, V A J ^a   Victorino, R M M ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Diagnostic tests; Drug hypersensitivity; Drug induced hepatitis; Prostaglandin E2; Specific T cells; Suppressor cells

Indexed keywords

ALLOPURINOL; AMINEPTINE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CAPTOPRIL; COTRIMOXAZOLE; ENALAPRIL; ERYTHROMYCIN; FENTIAZAC; FLUCLOXACILLIN; GLIBENCLAMIDE; GRISEOFULVIN; KETOCONAZOLE; NIMESULIDE; NITROFURANTOIN; PHENYTOIN; PROSTAGLANDIN INHIBITOR; PYRITINOL; SULPIRIDE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN CELL; LIVER TOXICITY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 9844252868     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.41.4.534     Document Type: Article

References (44)

1. Zimmerman HJ. Classification of hepatotoxins and mechanisms of toxicity. In: Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts, 1978: 91-121.
2. Shearman DJC, Finlayson NDC. Drugs, toxins and the liver. In: Diseases of the gastrointestinal tract and liver. London: Churchill Livingstone, 1989: 527-34.
3. Stricker BHC. Diagnosis and causality assessment of drug induced hepatic injury. In: Dukes MNG, ed. Drug-induced hepatic injury. Amsterdam: Elsevier, 1992: 1-21.
4. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95.
5. DeLeve LD, Kaplowitz N. Mechanisms of drug induced liver disease. Gastroenterol Clin North Am 1995; 4: 787-810.
6. Pohl LR. Drug induced allergic hepatitis. Semin Liver Dis 1990; 10: 305-15.
7. Pessayre D. Role of reactive metabolites in drug induced hepatitis. J Hepatol 1995; 23: 16-24.
8. Gómez-Lechón MJ, Carrasquer J, Berenguer J, Castell JV. Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug induced hepatitis. Clin Exp Allergy 1996; 26: 590-6.
9. Victorino RMM, Maria VAJ, Correia AP, de Moura MC. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 1987; 147: 987-9.
10. Maria VAJ, Silva JP, Victorino RMM. Agranulocytosis and liver damage associated to pyrazinobutazone with evidence for an immunological mechanism. J Rheumatol 1989; 16: 1484-5.
11. Maria VAJ, Victorino RMM. Hypersensitivity immune reaction as a mechanism of dilevalol associated hepatitis. Ann Pharmacother 1992; 26: 924-6.
12. Hofer T, Becker EW, Weigand K, Berg PA. Demonstration of sensitized lymphocytes to trimethoprim/sulfamethoxazole and ofloxacin in a patient with cholestatic hepatitis. J Hepatol 1992; 15: 262-3.
13. Tsutsui H, Terano Y, Sakagami C, Haseqawa I, Mizoguchi Y, Morisawa S. Drug specific T cells derived from patients with drug induced allergic hepatitis. J Immunol 1992; 149: 706-16.
14. Walton B, Dumonde DQ, Williams C, Jones D, Strunin JM, Layton JM, et al. Lymphocyte transformation. Absence of increased responses in alleged halothane jaundice. JAMA 1973; 225: 494-8.
15. Rotmensch HH, Leiser A, Dan M, Klyman A, Livini E, Ilie B, et al. Evaluation of prajmalium-induced cholestasis by immunological tests. Arch Intern Med 1981; 141: 1797-801.
16. Victorino RMM, Maria VAJ. Drug induced hepatitis and lymphocyte transformation test in presence of prostaglandin inhibitor. Lancet 1986; i: 1209-10.
17. Victorino R MM, Maria VAJ, Pinto L. Evidence for prostaglandin producing suppressor cells in drug induced hepatitis and implications in the diagnosis of drug sensitization. Clin Exp Immunol 1992; 87: 132-7.
18. Maria VAJ, Pinto L, Victorino RMM. Lymphocyte reactivity to ex-vivo drug antigens in drug induced hepatitis. J Hepatol 1994; 21: 151-8.
19. Benichou C. Criteria of drug induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
20. Danan G. Consensus meeting on causality assessment of drug induced liver injury. J Hepatol 1988; 7: 132-6.
21. Goodwin JS, Messner RP, Bankhurst AD, Peake GT, Saiki JH, Williams RC. Prostaglandin-producmg suppressor cells in Hodgkin's disease. N Engl J Med 1977; 297: 963-8.
22. Victorino RMM, Maria VAJ. Modifications of the lymphocyte transformation test in a case of drug induced cholestatic hepatitis. Diagnostic Immunology 1985; 3: 171-81.
23. Goodwin JS, Webb DR. Regulation of the immune response by prostaglandins. Clin Immunol Immunopathol 1980; 15: 106-22.
24. Kelleher D, Murphy A, Feighery C, Weir DG, Keeling PWN. Lymphocyte proliferation in inflammatory bowel disease: effect of monocyte suppressor cell. Eur J Gastroenterol Hepatol 1990; 2: 457-61.
25. Victorino RMM. Indomethacin sensitive suppressor cells in Crohn's disease: a possible role in decreased lymphocyte responsiveness. J Clin Lab Immunol 1983; 11: 197-201.
26. Foley P, Kazazi F, Biti R, Sorrell TC, Cunningham AL. HIV infection of monocytes inhibits the T-lymphocyte proliferative response to recall antigen, via production of cicosanoids. Immunology 1992; 75: 391-7.
27. Maria VAJ, Pinto LA, Victorino RMM. Inhibition of lymphocyte proliferation induced in vitro by microbial antigens in HIV-infected subjects. J Med Virol 1991; 35: 241-5.
28. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology 1997 (in press).
29. De Gruijl TD, Moore JJ, De Vries E, von Blomberg-van der Flier BME, Fonk JCM, Scheper RJ. Augmentation of antigenic-specific lymphoproliferative responses in vitro by biological response modifiers. Clin Exp Immunol 1994; 96: 535-40.
30. Tsujii H, Okamoto Y, Kikuchi E, Matsumoto M, Nakano H. Prostaglandin E, and rat liver regeneration. Gastroenterology 1993; 105: 495-9.
31. Cattral MS, Altraif I, Greig PD, Blendis L, Levy GA. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. Am J Med 1994; 97: 369-73.
32. Betz M, Fox BS. Prostaglandin inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol 1991; 146: 108-13.
33. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today 1991; 12: 319-52.
34. Liblau RS, Singer SM, McDevitt HO. Th1 and Th2 CD4 + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-8.
35. Brod SA, Benjamin D, Hafler DA. Restricted T cell expression of IL-2/IFN-γ mRNA in human inflammatory disease. J Immunol 1991; 147: 810-5.
36. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994; 91: 8562-6.
37. Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyota T. A case of drug induced ductopenia resulting in fatal biliary cirrhosis. Liver 1993; 13: 227-31.
38. Davies MH, Harrison RF, Eltas E, Hübscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged intrahepatic cholestasis. J Hepatol 1994; 20: 112-6.
39. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazo GF. Aberrant expression of HLA-DR antigens on bile duct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; ii: 1009-13.
40. Miyamoto T, Maeda T, Onishi S, Yamamoto Y. T cell auto-reactivity against a 28 kD biliary protein (B1-p28) in primary biliary cirrhosis. J Hepatol 1995; 22: 423-30.
41. Hasler F, Bluestein HG, Zvaifler NJ, Epstein LB. Analysis of the effects responsible for the impaired regulation of EBV-induced B cell proliferation by rheumatoid arthritis lymphocytes. J Immunol 1983; 131: 768-72.
42. Freilich BL, Hu KQ, Vierling JM. Immunopathogenesis of autoimmune hepatobiliary diseases. Curr Opin Gastroenterol 1994; 10: 257-68.
43. Hagley MT, Benak RL, Hulisz DT. Suspected cross-reactivity of enalapril and captopril-induced hepatotoxicity. Ann Pharmacother 1992; 26: 780-1.
44. Berg PA, Becker EW. The lymphocyte transformation test a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 1995; 22: 115-8.